Almirall SA
https://www.almirall.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Almirall SA
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
Finance Watch: The Biggest Biopharma IPO Of 2024 May Not Happen In The US
Public Company Edition: Galderma proposed pricing for its $2.6bn Swiss public market debut. Also, Apogee and Akero lead follow-on offerings with $483m and $366.9m, respectively, and Lexicon’s private placement brings in $250m, while Spruce reveals a 21% workforce reduction.
Almirall Casts Its Net To Cover Butterfly Skin Disease
Deal Snapshot: The Spanish company is linking up with US biotech Eloxx to get hold of an asset that will be its first in the rare dermatological disease space.
Galderma Reveals Long-Term Nemolizumab Data As It Prepares To Take On Dupixent
Galderma presented long-term extension data from its Phase III trials in atopic dermatitis and prurigo nodularis at AAD for its first-ever therapeutic biologic, taking on a formidable competitor.
Company Information
- Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Almirall S.A.
- Almirall LLC
- Aqua Pharmaceuticals
- Taurus Pharma GmbH
- Polichem S.A.
- Polichem S.r.l.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice